Description and characterization of the novel hyperthermia- and thermoablation-system MFH®300F for clinical magnetic fluid hyperthermia

被引:207
作者
Gneveckow, U
Jordan, A
Scholz, R
Brüss, V
Waldöfner, N
Ricke, J
Feussner, A
Hildebrandt, B
Rau, B
Wust, P
机构
[1] Charite Med Sch Berlin, Dept Radiat Med, Ctr Biomed Nanotechnol, D-14050 Berlin, Germany
[2] MFH Hyperthermiesyst GmbH, D-14050 Berlin, Germany
[3] MagForce Applicat GmbH, Dept Radiat Med, D-14050 Berlin, Germany
[4] Charite Med Sch Berlin, Dept Radiat Med, D-13353 Berlin, Germany
[5] Charite Med Sch Berlin, Dept Med Oncol, D-13353 Berlin, Germany
[6] Robert Rossle Hosp, Charite Med Sch Berlin, Dept Surg & Surg Oncol, D-13125 Berlin, Germany
关键词
hyperthermia; magnetic field; thermoablation; local tumor therapy; SAR; power; absorption;
D O I
10.1118/1.1748629
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Magnetic fluid hyperthermia (MFH) is a new approach to deposit heat power in deep tissues by overcoming limitations of conventional heat treatments. After infiltration of the target tissue with nanosized magnetic particles, the power of an alternating magnetic field is transformed into heat. The combination of the 100 kHz magnetic field applicator MFH(R)300F and the magnetofluid (MF), which both are designed for medical use, is investigated with respect to its dosage recommendations and clinical applicability. We found a magnetic field strength of up to 18 kA/m in a cylindrical treatment area of 20 cm diameter and aperture height up to 300 turn. The specific absorption rate (SAR) can be controlled directly by the magnetic field strength during the treatment. The relationship between magnetic field strength and the iron normalized SAR (SAR(Fe)) is only slightly depending on the concentration of the MF and can be used for planning the target SAR. The achievable energy absorption rates of the MF distributed in the tissue is sufficient for either hyperthermia or thermoablation. The fluid has a visible contrast in therapeutic concentrations on a CT scanner and can be detected down to 0.01 g/l Fe in the MRI. The system has proved its capability and practicability for heat treatment in deep regions of the human body. (C) 2004 American Association of Physicists in Medicine.
引用
收藏
页码:1444 / 1451
页数:8
相关论文
共 16 条
[11]   Interstitial thermal therapy in patients with localized prostate cancer: Histologic analysis [J].
Tucker, RD ;
Platz, CE ;
Huidobro, C ;
Larson, T .
UROLOGY, 2002, 60 (01) :166-169
[12]  
Van Der Zee J, 2002, INT J HYPERTHER, V18, P1
[13]  
Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731
[14]   CLINICAL, PHYSIOLOGICAL AND ANATOMICAL DETERMINANTS FOR RADIOFREQUENCY HYPERTHERMIA [J].
WUST, P ;
STAHL, H ;
LOFFEL, J ;
SEEBASS, M ;
RIESS, H ;
FELIX, R .
INTERNATIONAL JOURNAL OF HYPERTHERMIA, 1995, 11 (02) :151-167
[15]   Hyperthermia in combined treatment of cancer [J].
Wust, P ;
Hildebrandt, B ;
Sreenivasa, G ;
Rau, B ;
Gellermann, J ;
Riess, H ;
Felix, R ;
Schlag, PM .
LANCET ONCOLOGY, 2002, 3 (08) :487-497
[16]   Local hyperthermia of N2/N3 cervical lymph node metastases: Correlation of technical/thermal parameters and response [J].
Wust, P ;
Stahl, H ;
Dieckmann, K ;
Scheller, S ;
Loffel, J ;
Riess, H ;
Bier, J ;
Jahnke, V ;
Felix, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (03) :635-646